This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Obama Win Exposes Medical Stocks to QE Fatigue

Forecast 1-Year Return: Stocks with a red number are projected to decline by that percentage over the next 12 months. Stocks with a black number are projected to move higher by that percentage over the next 12 months.

Value Level: The price at which to enter a GTC Limit Order to buy on weakness. The letters mean; W-Weekly, M-Monthly, Q-Quarterly, S-Semiannual and A- Annual.

Pivot: A level between a value level and risky level that should be a magnet during the timeframe noted.

Risky Level: The price at which to enter a GTC Limit Order to sell on strength.

Abbott Labs (ABT - Get Report) ($64.52 vs $66.03 on Aug 8) still has a buy rating according to ValuEngine with the stock above its 200-day simple moving average at $62.89. My annual value level is $59.79 with a quarterly pivot at $63.28 and weekly risky level at $68.62.

Amgen (AMGN - Get Report) ($85.34 vs $81.57 on Aug 8) still has a buy rating and is above its 200-day SMA at $75.08. My quarterly value level lags at $77.19 with a weekly pivot at $86.33 and monthly risky level at $88.72.

Bristol-Myers (BMY - Get Report) ($32.62 vs $32.54 on Aug 8) still has a buy rating with the stock below its 200-day SMA at $33.42. My annual value level is $30.23 with a weekly pivot at $33.62 and monthly risky level at $35.67.

Express Scripts (ESRX - Get Report) ($54.95 vs $56.02 on Aug 8) still has a buy rating with the stock below its 200-day SMA at $56.77. My semiannual value level is $44.43 with a semiannual pivot at $53.18 and quarterly risky level at $58.12.

Gilead Sciences (GILD) ($65.45 vs $57.55 on Aug 8) has been downgraded to hold from buy since Aug. 8 with the stock above its 200-day SMA at $54.34. My quarterly value level is $60.53 with a monthly risky level at $68.87.

Johnson & Johnson (JNJ) ($70.34 vs $68.29 on Aug 8) still has a buy rating according to ValuEngine and is above its 200-day SMA at $66.53. My quarterly value level is $68.76 with an annual pivot at $70.65 with my annual risky level at $75.79.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ABT $46.25 0.00%
AMGN $163.58 0.00%
BMY $65.35 0.00%
ESRX $85.55 0.00%
XLV $73.29 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs